Skip to main content
PLOS One logoLink to PLOS One
. 2025 Jan 31;20(1):e0317960. doi: 10.1371/journal.pone.0317960

The urinary microbiome in association with diabetes and diabetic kidney disease: A systematic review

Tiscar Graells 1,*, Yi-Ting Lin 1,2, Shafqat Ahmad 3,4,5, Tove Fall 3, Johan Ärnlöv 1,6,7
Editor: Zongxin Ling8
PMCID: PMC11785297  PMID: 39888908

Abstract

Background

The urinary microbiome, or urobiome, is a novel area of research that has been gaining attention recently, as urine was thought to be sterile for years. There is limited information about the composition of the urobiome in health and disease. The urobiome may be affected by several factors and diseases such as diabetes, a disease that often leads to kidney damage. Thus, we need to understand the role of the urobiome to assess and monitor kidney disease related to diabetes over time.

Methods

We conducted a systematic review to summarize knowledge about the urobiome in association with diabetes mellitus and diabetic kidney disease. The search was conducted in several electronic databases until November 2024.

Results

Eighteen studies were selected including cross-sectional case-control studies, cross-sectional surveys and one prospective longitudinal study. In total, the urobiome of 1,571 people was sequenced, of which 662 people had diabetes, and of these 36 had confirmed diabetic kidney disease; 609 were healthy individuals, 179 had prediabetes or were at risk of type 2 diabetes mellitus and 121 did not have diabetes but had other comorbidities. Eight studies analysed data from females, one was focused on male data, and the other nine had mixed female-male data. Most of the studies had a small sample size, used voided midstream urine, and used 16S rRNA sequencing.

Conclusion

This systematic review summarizes trends seen throughout published data available to have a first baseline knowledge of the urinary microbiome, and its microbiota, in association with diabetes including the decreased richness and α-diversity in urinary microbiota in individuals with diabetes compared to healthy controls and the decreased α-diversity with the evolution of kidney disease independently of the cause.

1. Introduction

Microbial communities living within us comprise viruses, bacteria, archaea, and small eukaryotes like fungi and protists [1]. These communities are symbiotic microbial networks that can perform vital functions in the host and whose metabolites, or the lack of them, have influence in human health and diseases [24]. The intricate structure of these microbial ecosystems within their ecological niche, their taxonomy and functional composition, are known as the microbiome [5]. Similarly to our fingerprints, each microbiome in the gut, vagina, skin or urinary tract are highly unique and they are influenced by the environment, host genetics, lifestyle and there may be other factors influencing the microbiome for which we currently lack understanding [4]. Dysbiosis is a state where the microbiome is disrupted or altered, or both, impeding normal functionality or causing low-grade inflammation that may play a role in the onset and/or development of several diseases [5]. The human gut microbiome is seen as a “hidden” metabolic organ for human wellbeing affecting immunity, neural, endocrinal or metabolic pathways [4, 6]. Gut dysbiosis has been related to several diseases but if it is cause or effect of these diseases is a question that remains unclear [4, 7, 8]. While our understanding of the gut microbiome is evolving but limited, the knowledge about other microbiomes is even more scarce. This is particularly true for the urinary tract microbiome, or urobiome, which was long believed to be sterile until a decade ago [9, 10]. The urobiome is characterized by a low biomass relative to the gut microbiome, and its composition remains largely unexplored [9, 11]. Evidence suggests that the urobiome differs between males and females: associated with lactobacilli in females, whereas in males is linked to Corynebacterium or Staphylococcus [9, 11, 12].

Diabetes, a disease characterized by elevated levels of glucose in the blood, is a leading cause of cardiovascular disease, blindness or kidney damage [13]. Diabetes, especially type 2 diabetes mellitus (T2DM), has become a global health emergency whose prevalence have been rising for decades affecting 537 million people globally in 2021, including 6.7 million related deaths [13, 14]. The incidence of diagnosed diabetes in adults is stabilising in some high-income countries, but incidence in children is still increasing [1518]. Impaired glycaemia contributes to enhanced risk of infections, and it may explain why diabetic individuals have higher risk of urinary infections, pyelonephritis and urosepsis [19]. Not only individuals with diabetes have higher glucose, albumin and other proteins in urine which may affect the urobiome composition, enhance bacterial growth of some species and may influence the diversity of the urobiome; but also they have high glucose in urine which compromises the immune response and uroepithelial integrity [19]. However, we have limited information about the composition of the urobiome related to diabetes. In addition, damage in the kidney blood vessels, because of diabetes or other causes, may decline the estimated glomerular filtration rate (eGFR) which impacts urinary functions as these organs are connected through the ureters to the urinary bladder [20]. Development of diabetic nephropathy may further turn in chronic kidney disease (CKD) or end stage renal disease (ESRD), the former associated with diabetes but also other comorbidities while the latter is mostly caused by diabetes [20].

As there is a clear knowledge gap regarding the role of the urobiome in diabetes and diabetic kidney disease, the aim of this systematic review is to gather available data and synthetise the main findings about the urobiome, particularly, the urinary microbiota in association with diabetes and kidney conditions derived from diabetes such as CKD or ESRD.

2. Materials and methods

2.1 Search strategy

The comprehensive literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [21]. It was registered under accession number of 565545 in the International Prospective Register of Systematic Reviews (PROSPERO) hosted by the National Institute for Health and Care Research of the University of York (United Kingdom). A comprehensive literature search on different databases was conducted from 1st January 2000 until 28th November 2024. The search included the following terms [("urobiome" OR "urinary microbiome" OR "urinary microbiota" OR "urinary tract microb*" OR "urine microb*" OR "urogenital microbiome" OR "urogenital microbiota") AND ("kidney disease*" OR "chronic kidney disease" OR "diabetes" OR "albuminuria" OR "diabetic nephropathy" OR "end stage renal disease*" OR "renal disease*")]. We used the ‘TITLE-ABS-KEY’ search in SCOPUS and Cochrane Central Register of Controlled Trials databases, the ‘Keyword’ in advanced search in MEDLINE-Ovid and EMBASE databases, while ‘ALL FIELDS’ were used in Web of Science and PUBMED databases (S1 Table in S1 File). This search wanted to identify relevant clinical urinary microbiome studies associated with diabetes and/or kidney impairment published from 1st January 2000 until 28th November 2024.

2.2 Study selection

We included studies that evaluated the urobiome sequencing any type of urine samples (urinary bladder, urinary kidney or urogenital samples [22]) in relation with diabetes and conditions that affect kidney functionality, and which can lead to CKD or ESRD. Studies were excluded if they were review articles, editorials, comments, systematic reviews, books, conference abstracts or any other type of article without full data available. The inclusion criteria were: (i) analyses studying the bacterial species of urine; (ii) analyses of individuals with diabetes and/or albuminuria and/or diabetic CKD and/or diabetic ESRD; (iii) human clinical samples; and (iv) perform DNA sequencing through 16S ribosomal DNA gene or shotgun next generation sequencing.

2.3 Data extraction, assessment of quality and risk of bias

Throughout this synthesis, we used the PRISMA and PROSPERO frameworks and we incorporated the associated guidance at each stage. Following the removal of duplicates, the first step was the screening of studies by article type. After removal of non-suitable studies, the second step included a screening of studies by title and/or abstract for relevance. Those that seemed relevant were the preliminary selected publications and they were finally screened based on full-text information. Studies lacking full-text availability or with missing or unclear information were excluded from the evaluation (Fig 1). Two independent authors (T.G and Y.T.L) screened studies by title and abstract and, if discrepancies arose, they were discussed until they reached a common agreement. Preliminary selected publications were fully screened by T.G., reviewed by Y.T.L, and if they fulfilled the inclusion criteria, they were selected for this systematic review. Studies quality and risk of bias were assessed on participant selection, exclusion criteria, data measurements and analysis [23, 24]. A determination of “low risk” or “high risk” bias according to the Cochrane and the National Heart, Lung and Blood of the United States (NHLBI) guidelines was assessed by T.G. and independently checked by Y.T.L and J.Ä. [23, 25]. Any disagreement was discussed and resolved between these authors.

Fig 1. Flow diagram of selected studies.

Fig 1

Diagram showing how studies in this systematic review about the urinary microbiota and diabetes were selected.

3. Results

3.1 Selected studies

In total, eighteen studies were included including cross-sectional case-control studies, cross-sectional surveys and one prospective longitudinal study (Table 1 and S2 Table in S1 File). These studies altogether sequenced the urinary microbiome of 1,571 people, some participants were part of the same cohort studied and were included multiple times [2629]. Of these individuals 662 had diabetes, 609 were healthy individuals, 179 had prediabetes or were at risk of diabetes, and 121 did not have diabetes but had other comorbidities. Among the 662 diabetic individuals, 36 individuals had diabetic kidney disease [3032] while one studied CKD patients, most of them with diabetes, but did not mention the primary cause of CKD [33]. Sixteen of the studies used voided midstream urine samples, or a modification of this collection technique, to avoid as much as possible skin or genitalia microorganisms (S2 Table in S1 File). The remaining two studies analysed urinary bladder microbiota (catheterised urine) and, among these two, one was focused only on males (Table 1). Eight studies included only female samples (four of these used the same cohort data); and nine studies had mixed female-male data (Table 1). All studies except one used 16S sequencing which included twelve studies with small sample sizes with less than 100 individuals, including five studies with less than 50 participants (Table 1). The only one that used shotgun sequencing had a small sample size (n = 29) (S2 Table in S1 File). Participants of these 18 studies were adults; individuals with diabetes ranged between 50 and 72 years old on average, and healthy controls were similar in age but slightly younger (if age was significantly different between groups, it is stated in the comments in Table 1). Selected studies had comprehensive exclusion criteria which are detailed in S2 Table in S1 File and they were assessed for risk of bias in S3 Table in S1 File. Moreover, as articles considered confounding factors, such as age, BMI or other relevant clinical factors; those that were statistically significant between groups are pointed up in the comments of Table 1.

Table 1. Characteristics and results of selected studies.

Article Country Total adult Healthy vs diabetic adults Age: mean ± SD Context Indexes results in diabetic individuals Main findings and/or differences in relative abundance of diabetic individuals in urine Other significant details or relevant information
Case-control studies with controls and diabetic individuals
[34] China 30 0 vs 15 Kidney stones and T2DM:
56 ± 11
Kidney stones alone:
55 ± 12
Urinary microbiota in the renal pelvis of patients with kidney stones plus T2DM and those with kidney stones alone No differences in richness (Chao index)
α—diversity (Shannon index)
β-diversity: the group with kidney stones alone and with kidney stones and T2DM clustered and could be differentiated
Sphingomonas
Propionibacterium
Corynebacterium
Cellulosimicrobium
Methylophilus
Lactobacillus
Enhydrobacter
Chryseobacterium
Haemophilus
Allobaculum
The relative abundance of Enhydrobacter, Chryseobacterium, and Allobaculum
genera exhibited correlations with fasting blood glucose and HbA1c values.
[42] Italy 75 25 vs 50 H males:
62 ± 7
H females:
57 ± 6
T2DM males:
65 ± 9
T2DM females:
64 ± 10
No differences in richness or α—diversity (observed species, Chao, and Shannon indexes) NS
[Statistical differences in prevalence (males and females):
Bifidobacterium breve, Corynebacterium pyroviciproducens, Lactobacillus gasseri, and Streptococcus agalactiae were more prevalent in healthy controls. Campylobacter ureolyticus, Corynebacterium coyleae, Corynebacterium glucuronolyticum, Enterococcus faecalis, Escherichia coli, Lactobacillus iners, Peptoniphilus grossensis, and Veillonella atypica were more prevalent in T2DM individuals]
Total bacterial load and the abundance of total Bacillota were found to be elevated in patients with diabetes compared with the healthy control group, this was also true for females but not males.
Actinotignum schaalii, Bifidobacterium scardovii, Facklamia hominis, Negativicoccus succinicivorans, and Peptoniphilus lacrimalis were less prevalent in T2DM males. Aerococcus christensenii, Anaerococcus hydrogenalis, Brevibacterium ravenspurgense, Corynebacterium aurimucosum, Gardnerella vaginalis, Mobiluncus curtisii, Prevotella buccalis, Prevotella colorans, and Veillonella montpellierensis were more prevalent in T2DM females whereas Facklamia ignava and Winkia neuii were less prevalent in T2DM females.
[31] China 34 15 vs
19
H: 44 ± 8
T2DM:
60 ± 9
T2DM with diabetic kidney disease α—diversity
in T2DM
(Shannon and Simpson indexes)
Bacillota
Bacteroidota
Pseudomonadota
Acidobacteriota
Clinical characteristics between H and T2DM differed significantly in age; BMI; SBP; urea; uric acid; creatinine; natriuretic peptide; HbA1c (all in H); and HDL and albumin (both in H).
HbA1c was positively correlated with Acidobacteria and eGFR was positively correlated with Bacillota, Clostridiales, Clostridia, Lactobacillaceae and Lactobacillus.
[43] £ South Korea 691 368 vs 164 59 ± 6
(average of all groups and periods)
4-year longitudinal study of sequencing extracellular microbial vesicles. Also, 164 prediabetics and 35 people transitioned α—diversity
(Shannon index) in all groups
(possible effect of aging)
unclassified Lachnospiraceae GU174097_g Low abundance of GU174097_g was a risk factor for T2DM development, and it was associated with T2DM progression. GU174097_g decreased ketone bodies levels; and thus reduced HbA1c levels.
[37] Czech Repu-blic 58 0 vs 14 65 ± 14
(all)
Catheterized urine samples from men collected under anesthesia from the bladder prior to urological surgery. 14 individuals had diabetes (36 did not have diabetes and for 8 it was unknown) richness
(OTUs, ACE and iChao2 indexes)
α—diversity
(Shannon and Simpson indexes)
β—diversity
was no different
No statistical differences of specific taxa between T2DM and non-T2DM individuals Lower richness was also associated with: (1) ≥75 years; (2) High cholesterol and/or hyperlipidemia; (3) antibiotic prophylaxis.
Smokers had higher α—diversity.
No significant differences in α—diversity for hypertension or CKD.
β–diversity was different between individuals with (1) CKD vs no CKD; (2) severe vs mild urinary symptoms; and (3) antibiotic prophylaxis vs without
[40] ¥ Turkey 60 15 vs 15 H: 42 ± 11
Obese:
42 ± 9
Pre-DM:
50 ± 9
T2DM:
54 ± 8
T2DM, prediabetic (n = 15), obese (n = 15) and H groups NS Bifidobacterium (same was observed for obese and prediabetics) Clinical features statistically different: FBG between all groups; HbA1c between all groups except for H and obese individuals; BMI between all groups except for prediabetics and both obese and T2DM. Age was significantly lower in both H and obese vs T2DM individuals. Triglycerides and HDL were significantly lower in H vs both prediabetics and T2DM individuals
[36] United States 136 49 vs 87 H: 51 ±11
T2DM:
51 ± 11
Females with T2DM β–diversity:
Both H and T2DM clustered in 4–5 urotypes
Urotypes in T2DM:
Lactobacillus and Enterobacteriaceae vs
H females: Gardnerella and mixed
Lactobacillus
Corynebacterium
Staphylococcus
[T2DM differences in presence/absence:
Lactobacillus was more present while Corynebacterium, Anaerococcus, Finegoldia and Peptoniphilus were less present]
H and T2DM groups differed significantly in FBG and HbA1c (both in H). HbA1c was positively correlated with Lactobacillus and negatively associated with Prevotella and Corynebacterium in all cohort; and negatively associated with Prevotella also in the T2DM group.
Prevalence of Lactobacillus increased with weight; and most of participants were obese.
[35] China 58 26 vs 32 H: 58 ± 9
T2DM:
57 ± 8
Females H and T2DM. T2DM microbiota were also assessed for lower urinary symptoms and levels of HbA1c Richness and α–diversity were no different (OTUs, observed species, Chao, ACE, Shannon and Simpson indexes)
β—diversity
was different between H and T2DM
Escherichia-Shigella
Klebsiella
Aerococcus
Delftia
Enterococcus
Alistipes
Stenotrophomonas
Micrococcus
Deinococcus
Gallicola
Arcobacter
Arcanobacterium
Kocuria
Murdochiella
Solitalea
Peptoniphilus
FBG was in T2DM compared to H group.
HbA1c was in T2DM with urinary symptoms vs T2DM without.
The diabetic group with urinary symptoms (compared to the group without) had lower richness, different β–diversity; and:
Escherichia-Shigella
Campylobacter
Megasphera
Prevotella
Dialister
Anaerococcus
Fusobacterium
Prevotella_6,
Mycoplasma
Peptoniphilus
Porphyromonas
Fodinicola
Brevundimonas
The diabetic group with high HbA1c compared to the diabetic low HbA1c group had lower α–diversity, different β–diversity, and:
Escherichia-Shigella
Lactobacillus
Prevotella
Campylobacter
Dialister
Anaerococcus
Peptoniphilus
Porphyromonas
Fodinicola
[39] China 100 50 vs 50 Elderly:
72 ± 7
Non-old:
50 ± 8
Elderly vs non-elderly cohorts. Half of the females of each cohort had T2DM richness
(OTU and Chao indexes) in elderly with T2DM
No differences in α—diversity (Shannon and Simpson indexes) between the elderly with and without T2DM
Elderly with T2DM (compared to elderly without):
Nitrospirae
Odoribacter
Aeromonas
Clostridium
Enterobacter
Butyricimonas
Enterococcus
Erwinia
Fusobacterium
Klebsiella
Lachnobacterium
Stenotrophomonas
Phascolarctobacterium
Eggerthella
Parvimonas
Bdellovibrio
Hydrogenophaga
Lactobacillus iners
T2DM females treated with metformin. Lactobacillus had a decreased trend in T2DM patients with FBG > 10 mmol/l.
Lactobacillus iners was not associated with FBG.
Elderly related differences: (1) relative abundance of Bacillota (Firmicutes) increased with BMI; (2) relative abundance of Bifidobacteria was negatively correlated with age; (3) Lactobacillus decreased with age but was not associated with pH; (4) abundance of Sphingobium and Bosea; and (5) abundance of Sneathia; Geobacillus; Shuttleworthia; Bacillus; Gemella; Bdellovibrio; Hydrogenophaga; Proteus; Novosphingobium.
[26] China 140 70 vs 70 Matched H and T2DM individuals.
70% > 56 years or older; only 8% younger than 45 years
Authors matched individual characteristics between the H and the T2DM groups richness
(number of OTUs, observed species, ACE and Chao1 indexes)
α-diversity (Shannon index)
Actinobacteria
Porphyromonas
Flavobacteriales
Collinsella
Akkermansia muciniphila
Bacteroidota
Prevotellaceae
Prevotella
Pseudomonadales
Peptoniphilus
Citrobacter
Actinobacteriota
Synergistota
Acinetobacter
Campylobacter
Campylobacterales
Staphylococcus
Anaerococcus
Halomonas
Finegoldia
Streptococcus
Veillonella
Clostridium
Corynebacterium
Actinobacteria increase was associated with higher BMI; increased FBG and urine glucose.
Akkermansia muciniphila decrease was associated with FBG and urine glucose.
Urine glucose, FBG, urine infections, hypertension and hyperlipidemia were statistically in T2DM compared to H group.
Authors studied hypertension and hyperlipidemia in article by [28]; inflammatory markers in article by (Ling et al. 2017) and the effect on diet in article 7 [29].
[32] United States 29 8 vs 6 H: 35
ESDR T1DM: 51
ESDR T2DM: 64
(all ESRD: 53)
Transplant ESRD patients. Kidney damage caused by 4 primary diagnoses: other, T1DM, T2DM, and hypertension.
15 individuals had non-diabetic ESRD.
Trimethoprim -sulfamethoxazole was given prophylactically
α-diversity (Shannon and inverse Simpson indexes)
richness (observed species)
β-diversity: primary diagnoses had no significant differences in bacterial composition; but all had with the H
Enterococcus faecalis
Enterococcus faecium
Enterococcus sp.
Escherichia coli
Escherichia sp.
Cutibacterium acnes
Corynebacterium
Mobiluncus curtisii
Bacillota and Actinobacteria because Enterococcus belongs to the former phylum while as Mobiluncus belongs to the latter.
Both groups had similar folate metabolism (which is the target of trimethoprim -sulfamethoxazole) but had differences in specific enzymes. Dihydrofolate synthase/folypolygluta-mate synthase was increased in transplant groups.
Studies with diabetic individuals only
[41] Taiwan 7 0 vs 7 T2DM No-pyuria: 59 ± 6
T2DM Pyuria: 60 ± 7
All 7 individuals with T2DM and SGLT2
therapy; 3 with pyuria in urine; 4 without
α—diversity
in T2DM with pyuria compared with T2DM without pyuria (Shannon index)
Escherichia-Shigella in individuals with pyuria 7 T2DM individuals with negative standard urine cultures. eGFR stage II (60–89 mL/min) mildly impaired kidney function
[38] China 30 0 vs 30 T2DM with diabetic peripheral neuropathy:
56 ± 8
T2DM only:
55 ± 7
Among the 30 females with T2DM, 17 females also had diabetic peripheral neuropathy richness in DPN group (OTUs, observed species, ACE and iChao2 indexes)
α–diversity was no different
(Shannon and Simpson indexes)
β–diversity was no different
Group with DPN:
Mycoplasmataceae Propionibacteriaceae
Pseudobdellovibrioinaceae Sphingobacteriaceae
T2DM females: 17 with DPN and 13 without.
Both groups did not differ in clinical characteristics.
* [28] China 70 0 vs 70 T2DM:
56 ± 14
T2DM + hypertension:
70 ± 9
T2DM + hyperlipidemia:
54 ± 11
T2DM + both: 70 ± 10
Only analysis of the T2DM individuals from article 13 that had different clinical features. The T2DM cohort was divided: 28 had T2DM; 24 had T2DM + hypertension; 7 had T2DM + hyperlipidaemia; 11 had T2DM and both hypertension + hyperlipidaemia richness compared to the hyperlipidemia only group (number of reads and number of OTUs)
richness compared to hypertension groups (number of reads and number of OTUs)
No differences in α—diversity (Shannon and Simpson indexes) between the groups
Compared to T2DM + hypertension group, the group with only T2DM had:
Lactobacillus iners
Acinetobacter rhizosphaerae
Acinetobacter schindleri
Lactobacillus
Enterobacter
Klebsiella
Shuttleworthia
Sneathia
Parvimonas
Megasphera
Erwinia
Kocuria palustris
Aeromonas
Roseburia
Ruminococcus
Compared to T2DM + hyperlipidemia, the group with only T2DM had:
Faecalibacterium
Collinsella
Oscillospira (diagnostic factor to differentiate both groups)
Compared to T2DM + hypertension and hyperlipidemia, the group with only T2DM had:
Acinetobacter rhizosphaerae
Shuttleworthia
Gemella
Prevotella
Compared to T2DM + hypertension and hyperlipidemia, the group with T2DM + hyperlipidemia had:
Acinetobacter rhizosphaerae
Faecalibacterium
Compared to T2DM + hypertension, the group with T2DM + hyperlipidemia had:
Klebsiella
Novosphingobium
Lactobacillus
Enterobacter
The two groups with hypertension did not show differences
The T2DM cohort was divided: 28 T2DM; 24 T2DM + hypertension; 7 T2DM + hyperlipidemia; 11 T2DM + hypertension + hyperlipidemia. The duration of T2DM was significantly shorter in the two groups without hypertension.
The four most abundant bacteria in all groups were Proteobacteria, Bacillota, Bacteroidota and Actinobacteria. The fifth varied from Fusobacteria (inT2DM and T2DM with both conditions), Synergistota (group with hypertension) and Acidobacteria (group with hyperlipidemia).
Predominant genera: in T2DM Lactobacillus, Prevotella, and Acinetobacter; in T2DM + hyperlipidemia Lactobacillus, Prevotella and Halomonas; in T2DM + hypertension Prevotella, Streptococcus, and Bacteroides; and in T2DM + hypertension + hyperlipidemia Prevotella, Lactobacillus and Bacillus.
The groups with hypertension had presence of Eggerthella lenta but this species was absent in the group with only diabetes; while Gardnerella was absent in the hyperlipidemia group but it was present in the other groups.
Several bacteria correlated with FBG, blood pressure and lipidic profiles. Atopobium was positively correlated with FBG in the T2DM group. Allobaculum and Odoribacter were negatively correlated with diastolic pressure in the hypertension and hypertension plus hyperlipidemia groups, respectively. Rikenella and Dorea were positively correlated with triglycerides in the hyperlipidemia group and with LDL in the hypertension plus hyperlipidemia group, respectively.
* [27] China 70 0 vs 70 T2DM with IL-8 in urine:
66 ± 14
T2DM without IL-8 in urine:
59 ± 11
T2DM females whose levels of IL-8 were evaluated. IL-8 is a potential biomarker for diagnosing of urinary infections α–diversity was no different between T2DM females with and without IL-8 in urine (Shannon and Simpson indexes)
β-diversity: the group with Il-8 and without IL-8 in urine clustered together and could be differentiated
T2DM females without IL-8:
Bifidobacteriaceae Shuttleworthia
Thermales
Streptococcus anginosus
Acinetobacter rhizosphaerae
Acinetobacter schindleri
Lactobacillus iners
Akkermansia muciniphila
Mobiluncus
Peptoniphilus
Corynebacterium
Gemella
Enterococcus
Geobacillus
Prevotella copri
Prevotella stercorea Bacteroides uniformis Coprococcus eutactus
Faecalibacterium
Megamonas
Comamonas
Pseudomonas
Phascolarctobacterium

Ruminococcus was positively associated with urinary IL-8.
Urinary IL-8 was high in T2DM patients with Pseudomonas and Klebsiella.
Clinical features between the T2DM with IL-8 and without IL-8 in urine differed in age, BMI and pH, white blood cells, leukocyte esterase, protein, glucose, and nitrites in urine (all characteristics in the group with IL-8)
* [29] China 140 70 vs 70 Matched H and T2DM individuals.
70% > 56 years or older; only 8% younger than 45 years
T2DM association with urinary IL-8 and evaluation of the effect of diet on urinary microbiota NS NS Ruminococcus was positively associated with urinary IL-8 (results from Ling et al. 2017). Water weakened the positive relationship between Ruminococcus and IL-8 in urine while fiber, vitamin B3 and vitamin E enhanced the positive relationship.
Case-control studies with individuals that have kidney or renal disease
[30] Portu-gal 46 0 vs 14 57 ± 11 All individuals with CKD and on peritoneal dialysis; the rest had other comorbidities α—diversity (Shannon index) as CKD-PD worsened (independently of the cause) Atopobium
Dermabacter
Gardnerella
Apart from diabetes in CKD patients, significance was found for sex: Lactobacillus linked to females; Staphylococcus and Anaerococcus to males.
[33] United States 77 23 vs 54 Males: 77 ± 8 Females:
71 ± 8
All individuals with CKD but no dialysis (70% of them with diabetes) α—diversity (Shannon index) as CKD worsened (independently of cause).
Richness and α–diversity were no different between diabetic and non-diabetic CKD individuals (Chao; Inverse Simpson and Shannon indexes).
NS Richness and α–diversity were no different by age or obesity status.
β–diversity: Different urotypes.
Urinary incontinence and eGFR was associated with α-diversity.

BMI = body mass index; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; ESRD = end stage renal disease; FBG = fasting blood glucose; H = healthy controls; HbA1c = glycosylated haemoglobin; IL-8 = interleukin 8; NS = Not stated; OTU = operational taxonomic unit; PD = peritoneal dialysis; SBP = systolic blood pressure; (TX)DM = (type X = 1 or X = 2) Diabetes mellitus; SD = standard deviation; vs = versus;

* = studies that used data from participants/cohort of article 13 authored by Liu et al. 2017 [26];

£ = sequencing of microbiota extracellular vesicles;

¥ = primers for phylum Firmicutes; and genera Bacteroides and Bifidobacterium;

= some or all individuals used antibiotic prophylaxis.

= only females;

= only males;

= lower;

= higher.

3.2 Diversity and richness indexes

Among the 11 case-control studies, 9 reported richness and α-diversity analyses of which three of the studies observed a decrease in richness and α-diversity, one a decrease in richness, two a decrease in α-diversity, one observed an increase in α-diversity but this study assessed kidney stones patients with and without diabetes, and two studies did not observe differences in richness or α-diversity in the urobiome of the individuals with diabetes compared to those without diabetes (Table 1). Among the studies assessing only diabetic individuals, one study observed lower α-diversity in diabetic individuals with pyuria, one study observed lower richness in patients with diabetic peripheral neuropathy, one study did not observed differences in α-diversity when assessing urinary interleukin-8; and one study observed increased richness in diabetic individuals compared to diabetic individuals with hyperlipidaemia but decreased richness if compared to diabetic individuals with hypertension. Lastly, the two studies assessing CKD reported a decrease of α-diversity as CKD worsened independently of the primary cause of CDK (diabetes or other). Indexes calculated in each study are detailed in S4 Table in S1 File and the main ones are detailed in Table 1. Only seven studies reported β-diversity analyses with variable results (Table 1); 4 reported differences in β-diversity, of which 2 described different urotypes [3336]; while 3 did not see differences in β-diversity [27, 37, 38].

3.3 Differences in microbial taxa

Significant results in microbial species for diabetic adults (statistical significance set to p< 0.05) of each article are summarised in Table 1 and all details can be found in S5 Table in S1 File. Comprising all studies, most of the bacterial species were identified at the genus level; few at species level and some at higher taxonomy levels. The relative abundance of 69 different bacteria was decreased, of 53 was increased in the urine of diabetic individuals while bacteria such as Enterococcus, Stenotrophomonas, Klebsiella or Actinobacteriota had increased or decreased relative abundance depending on studies (S5 and S6 Tables in S1 File and Table 1).

Overall, we could observe that the genus Lactobacillus, and at species level Lactobacillus iners, had increased relative abundance in diabetic individuals in 6 and 2 studies, respectively; and it was related to poor glycaemic control and with presence of interleukin-8 in urine [27, 28, 3436, 39]. Three studies reported a decrease in relative abundance of the family Bifidobacteriaceae in urine of individuals with diabetes which includes the genera Bifidobacterium and Gardnerella; while one study reported the absence of the genus Gardnerella in individuals with diabetes and hyperlipidemia (note: Gardnerella is included now in the genus Bifidobacterium)[27, 28, 30, 40]. In addition, depletion of the family Peptoniphilaceae in urine of T2DM patients was reported in several selected studies. In fact, studies reported decreased relative abundance of this family being relevant genera Peptoniphilus, Anaerococcus, Finegoldia, Murdochiella and Gallicola, which were reported decreased abundant in four, three, two, one and one article, respectively [26, 27, 35, 36]. The genus Parvimonas, which belongs to this family as well, was increased in relative abundance in diabetic individuals compared to non-diabetics only in the elderly cohort [39]; while its relative abundance was increased in the diabetic cohort compared to the diabetic plus hypertension cohort [28]. Lastly, three studies reported increased relative abundance of Escherichia (Escherichia-Shigella), a well-known genus causing urinary tract infections (UTI), which was related to poor glycaemic control and in two studies this genus was related to urinary symptoms or pyuria in urine (even though individuals did not have an active UTI) [32, 35, 41].

Taxonomic classification of bacteria identified in selected studies was updated according to Genome Taxonomy Database release 220 (https://gtdb.ecogenomic.org/) at higher taxonomical levels (e.g. phylum) but at lower levels was maintained to preserve clarity of the conclusions. For the most accurate taxonomic annotation refer to details in S6 Table in S1 File.

4. Discussion

This study has assessed the urinary microbiota related to diabetes and diabetes-related kidney diseases through a systematic review. This work has summarised statistically significant results reported by selected studies with a threshold of p ≤ 0.05. The main findings of this study were: (1) a decreased richness and α-diversity in urinary microbiota in individuals with diabetes compared to healthy controls; (2) α-diversity was not different within diabetic individuals, except if they showed urinary symptoms (e.g. urgency to pee) although they did not have a (diagnosed) urinary infection; (3) α-diversity decreases with the evolution of kidney disease independently of the primary cause (e.g. kidney disease primarily caused by diabetes or hypertension or other pathology); (4) β-diversity urinary microbiota composition between healthy controls and diabetic individuals results were conflicting between studies and may depend on the stage of the disease and/or the grade of kidney damage; (5) patients with T2DM shared the depletion of Peptoniphilus, Anaerococcus, Finegoldia and Gallicola (all formerly part of the genus Peptostreptococcus and inside the Peptoniphilaceae family), or Lachnospiraceae that are butyrate-producing bacteria; (6) patients with diabetes shared the enrichment of pro-inflammatory microbes such as Pseudomonadota (formerly Proteobacteria) and of bacteria of order Lactobacillales such as Lactobacillus or Enterococcus; (7) cohort sizes were small (from a few samples to more than one hundred) and the only one study that was large (nearly seven hundred samples) had data restricted to extracellular microbial vesicles; (8) except in two studies, voided midstream urine samples were analysed and those are often referred as urogenital samples due to likely cross-contamination with skin or genitalia microbiota during collection; and, (9) although data showed similar trends, some bacterial phyla, families, and genera had controversial results, probably due to the lack of resolution of these studies using 16S sequencing.

One of the main findings of this systematic review is the depletion of the family Peptoniphilaceae in urine of T2DM patients as a trend. The most relevant genera of this family for the urobiome being Peptoniphilus, Anaerococcus, Finegoldia, Murdochiella, Parvimonas and Gallicola. These genera are gram-positive obligate anaerobic cocci that have been described as producers of short-chain fatty acids such as butyrate (Peptoniphilus, Anaerococcus, and Gallicola) and acetate (Peptoniphilus, Parvimonnas, Gallicola and Finegoldia) or lactate (Murdochiella) [44]. Parvimonas increased in relative abundance in diabetic individuals compared to non-diabetics only in the elderly cohort [39]; while its relative abundance was increased in the diabetic cohort compared to the diabetic plus hypertension cohort [28]. In the latter, if diabetes is accompanied by other factors such as hypertension, there is decreased abundance of this genus pointing to a depletion as the health status worsens. Peptoniphilus and Anaerococcus abundance may be associated to glycosylated haemoglobin HbA1c as diabetic individuals with high HbA1c had decreased relative abundance of these two genera in urine compared to diabetic individuals with low HbA1c [35]. Generally, adults with diabetes and/or CKD show lower abundance of short-chain fatty acids producing bacteria in the gut compared to healthy controls [4, 45]. This systematic review reveals that diabetic individuals have similar trends in their urinary and urogenital microbiota with lower relative abundance of short-fatty acid butyrate-producing bacteria of the family Peptoniphilaceae. Butyrate is the main source of colonocyte metabolism, it is an enhancer of the integrity of the epithelium, and it decreases inflammation in the mucosa while promoting electrolyte absorption in the gut [46]. Moreover, dissociated butyric acid has an antibacterial effect [46] and butyryl-CoA regulates transcription and modifies proteins [46, 47]. We hypothesize that butyrate could also promote epithelium integrity and reduce inflammation in the urinary tract. Hence, depletion of butyrate-producing bacteria such as Peptoniphilus, Anaerococcus, and Gallicola in diabetic individuals could induce inflammation and contribute to the high onset of urinary infections in diabetic individuals in the urinary tract and induce inflammation in the renal blood vessels which could worsen kidney disease. This theory will need further studies to be tested, and it could help to understand if these molecules could be used to improve urinary functionality in association with diabetes and kidney disease.

Higher relative abundance of Lactobacillus associated with diabetes was a common trend of this systematic review. Lactobacillus have been described as a genus that is common in the urobiome of females and whose difference between females and males has been attributed to the hormone oestrogen, which plays a crucial role in glycogen production [11, 48]. Oestrogen fluctuations with age and menopausal status may affect the female urobiome [49], as the genus Lactobacillus metabolizes glycogen, and as a byproduct of it there is lactic acid which acidifies the environment modulating the growth of other bacteria [11]. The acidic environment has been assumed significant for the protective role that lactobacilli play in both the vaginal and urinary microbiomes of women [9, 48]. However, the genus Lactobacillus seems to be more abundant in the urine of diabetic individuals according to this systematic review. In line with these findings, history of diabetes was associated with increased odds of growing Lactobacilli when using expanded quantitative urine culture in catheterised urine of women [50]. Lactobacillus iners, which has been described as a transitional species that colonizes the vagina after an ecological disturbance [51], was found enriched in the urine of T2DM females [28, 39] and in the same cohort with higher levels of inflammatory interleukin-8 in urine [27]. Other species of this genus such as Lactobacillus crispatus and Lactobacillus gasseri have been associated with lack of lower urinary tract symptoms and lack of urgency urinary incontinence, respectively; and levels of Lactobacillus in the vagina are reported to be associated with menopausal status and with reduced risk of UTI [36]. Although lactobacilli have generally been considered beneficial and the normal microbiota of the urobiome and vagina, there is increasing evidence that some Lactobacillus spp. may be pathogenic or related to urinary symptoms [52, 53]. The association between the different species of Lactobacillus and their role in T2DM needs further investigation, considering that age, oestrogen, HbA1c and/or BMI could also be important factors affecting the abundance of this genus. In this context, HbA1c was positively correlated with Lactobacillus. Individuals with T2DM and high HbA1c had higher abundance of this genus compared to those with T2DM and low HbA1c levels [35, 36]. Another point to consider is that the genus Lactobacillus is naturally resistant to widely used antibiotics and T2DM individuals often have multiple infections that require the use of them [35]. Thus, we could hypothesize that antibiotic therapy may imbalance the urobiome allowing Lactobacillus to grow excessively which may induce inflammation.

Diabetic, prediabetic and obese individuals had lower abundance of the genus Bifidobacterium in urine; and the abundance of this genus was negatively correlated with age [39, 40]. In this line, T2DM patients with hyperlipidemia lacked Bifidobacterium (former Gardnerella) [28]. This was also true for the former genus Gardnerella, that is now included in the genus Bifidobacterium, that have decreased abundance in CKD patients with diabetes [30]. Bifidobacterium (Gardnerella) was a common urotype in healthy females compared to diabetic females that had Lactobacillus or Enterobacteriaceae urotypes [36]. Bifidobacteriaceae had decreased relative abundance in diabetic females without interleukin-8 in urine in the study by Ling et al; but this group had also lower age and BMI compared to the group with interleukin-8 [27]. These results may imply that diabetes but also age, BMI or levels of interleukin-8 could influence the relative abundance of Bifidobacterium in urine [27].

The role of the genus Prevotella in the urinary microbiota is unclear. Although HbA1c was negatively correlated with Prevotella in T2DM patients [36] and Chen et al. reported a decrease of this genus in individuals with diabetes with high urinary symptoms [35], other studies have found that this genus was more prevalent in T2DM [42] or that urotypes and enrichment of Prevotella was associated with urinary incontinence patients [12, 54]. Therefore, similarly to findings with the genus Lactobacillus, we will likely need higher resolution studies, preferably shotgun metagenomics, to identify which species or strains of these genera may play different roles in the urobiome.

UTIs are common in diabetic patients and are associated with poor glycaemic control, which compromises kidney function and impairs quality of life [55]. That is why many selected articles also examined urinary symptoms, as hospitalization for UTIs caused by diabetes is more than twice as common as hospitalizations for UTIs caused by other factors. The use of sodium–glucose cotransporter 2 inhibitors as therapy for diabetes may contribute as these drugs reduce glucose reabsorption, thus lowering the level on blood, but causing glycosuria in urine which could increase the risk of UTIs in those patients [56]. Hyperglycaemia and diabetes have shown to reduce psoriasin and occludins levels in the urinary tract leading to be more prone to urinary tract infections [19]. Moreover, psoriasin is an antimicrobial peptide with a broad protective role against Escherichia coli and Enterococcus urinary infections, two of the most common pathogens causing UTI in diabetics [19]. In addition, low-grade inflammation with higher concentration of proinflammatory cytokines and the depletion of producers of short-chained fatty acids such as butyrate, which has beneficial effects on the host [57], may affect mucosa integrity, bacterial translocation and host–urine microbiota interactions in T2DM patients.

The results of this systematic review have also highlighted that urinary microbiota diversity seems lower in CKD or ESRD and it drops as the disease progresses independently of the primary cause [30, 33]. Diabetes progression to kidney damage reduces eGFR and as eGFR declines the excretion of uromodulin follows the same trend. Uromodulin, an urinary antimicrobial peptide whose function is to stick to bacteria forming larger particles which enhance their excretion by the kidney, is produced exclusively in the renal tubules and is affected by the decline of renal function [33] which may also influence bacterial growth, microbiota diversity and risk of UTI.

4.1 Strengths and limitations

To our knowledge, this review represents the first comprehensive analysis of the current understanding of the urobiome, specifically the urinary microbiota, in the context of diabetes. One notable strength of this review is the identification of emerging trends within the urobiome across multiple studies where the majority had low risk of bias assessment. For instance, this is the first article to highlight the significance of the Peptoniphilaceae family within the urobiome of diabetic individuals, which has frequently been reported as less prevalent or reduced in relative abundance in urine of diabetic individuals. Additionally, this work is strengthened by its systematic approach, adhering to PRISMA and PROSPERO guidelines, ensuring standardized and reproducible results.

However, we also recognize some limitations. First, we were unable to perform meta-analyses due to the considerable heterogeneity of the included studies and the small sample size in most of them. Second, the included studies have some methodological limitations such as the collection method of the urine, the small sample size of the studies, being the vast majority cross-sectional, and mostly they processed samples using 16S sequencing. Only two studies analysed catheterized urine, reflecting the microbiota of the bladder or renal pelvis, while most of the studies relied in voided midstream collection techniques that may also capture microbiota from the genitalia or skin (Linda Brubaker et al., 2021). Since most studies employed 16S sequencing, the resolution of the results is limited and there may be discrepancies depending on the region sequenced (most of them used the V3-V4 region or only the V4 region of the 16S rDNA gene). This limitation means that the same genera identified across different studies could refer to distinct bacterial species, potentially explaining some discrepancies in the findings. Moreover, microbial taxa such as fungi or small prokaryotic taxa that may also contribute to the urobiome community are often not captured in these studies, as they must sequence the eukaryotic 18S rDNA gene. Another limitation is the evolving taxonomical classification of bacteria. Taxonomic reclassification may have occurred since the original articles were published. Where possible, we have updated higher-level classifications (e.g., from Firmicutes to Bacillota) while maintaining the original nomenclature at lower levels to preserve the clarity of the conclusions (e.g., Gardnerella instead of Bifidobacterium). For the most accurate taxonomic annotation, we refer readers to the Genome Taxonomy Database release 220 (https://gtdb.ecogenomic.org/), with detailed information provided in S6 Table in S1 File. Therefore, the generality of these findings may be treated as trends, with caution, and these hypotheses should be tested in larger size studies and analysed using high resolution shotgun sequencing.

5. Future perspectives

There are significant knowledge gaps regarding the role and impact of the urobiome in both health and disease. This emerging field has attracted increasing attention in recent years, but the influence of the urobiome on conditions such as diabetes and diabetic kidney disease remains largely unexplored. While this systematic review has identified common trends across studies—such as the depletion of Peptoniphilaceae and the increased abundance of Lactobacillus in the urine of diabetic adults—the evidence remains insufficient due to the small sample sizes of most studies and the limited resolution provided by 16S sequencing.

To advance urobiome research, large-scale population-based studies are urgently needed, along with the application of higher-resolution techniques like shotgun metagenomics to more precisely characterize the urinary microbiome. Longitudinal studies will also help to understand the changes in the urinary microbiome in diabetes and diabetic kidney disease progression, including the role of the urobiome in early stages of diabetes development. These approaches could identify generalized results including specific microbial species that play critical roles in maintaining a healthy urobiome, as well as those involved in the onset and progression of diseases such as diabetes and conditions affecting kidney function. In the future, the applicability of this knowledge may help us to investigate the influence of diet on the urobiome in diabetes and the potential for probiotics, postbiotics or other interventions to modulate the urobiome in relation to diabetes and diabetic kidney disease.

Supporting information

S1 File

(DOCX)

pone.0317960.s001.docx (185.6KB, docx)
S1 Checklist. PRISMA 2020 checklist.

(DOCX)

pone.0317960.s002.docx (31.7KB, docx)
S1 Table. Original records retrieved from Pubmed, SCOPUS, MEDLINE-Ovid, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials databases.

(XLSX)

pone.0317960.s003.xlsx (71.6KB, xlsx)

Data Availability

Data presented and gathered in this systematic review are fully shown in this manuscript or in the supplementary information.

Funding Statement

We acknowledge funding from the Swedish research council (Vetenskapsrådet grant number 2019-01015 (J.Ä.), 2019-01471 (T.F.) and 2020-0243 (J.Ä.)), from the Swedish heart lung foundation (Hjärt-Lungfonden grant number 2021-0357 (J.Ä.), 2023-0687 (T.F.) and 2024-0486 (J.Ä.)), and from Center of clinical research (CKF) in Region Dalarna, Falun, Sweden. Dr Ahmad was supported by research grants from FORMAS–Early Career Grant (no. 2020-00989), Swedish Research Council-Early Career Grant (no. 2022-01460), EFSD/Novo Nordisk and EpiHealth. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020. Nov 24;10:572912. doi: 10.3389/fcimb.2020.572912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kirby TO, Hendrix EK, Ochoa-Repáraz J. The gut microbiota as a therapeutic approach for obesity. In: Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications. Elsevier; 2019. p. 227–34. [Google Scholar]
  • 3.Aasmets O, Krigul KL, Lüll K, Metspalu A, Org E. Gut metagenome associations with extensive digital health data in a volunteer-based Estonian microbiome cohort. Nat Commun. 2022;13(1):1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021. Jan 4;19(1):55–71. doi: 10.1038/s41579-020-0433-9 [DOI] [PubMed] [Google Scholar]
  • 5.Berg G, Rybakova D, Fischer D, Cernava T, Vergès MCC, Charles T, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020. Jun 30;8(1):1–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Ther Adv Gastroenterol. 2013;6(4):295. doi: 10.1177/1756283X13482996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of Intestinal Barrier Dysfunction in Gut Dysbiosis and Diseases. Biomedicines. 2022. Jan 27;10(2):289. doi: 10.3390/biomedicines10020289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016. Jan;14(1):20–32. doi: 10.1038/nrmicro3552 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Roth RS, Liden M, Huttner A. The urobiome in men and women: a clinical review. Clin Microbiol Infect. 2022;▪:1. doi: 10.1016/j.cmi.2022.08.010 [DOI] [PubMed] [Google Scholar]
  • 10.Hilt EE, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine Is Not Sterile: Use of Enhanced Urine Culture Techniques To Detect Resident Bacterial Flora in the Adult Female Bladder. Munson E, editor. J Clin Microbiol. 2014. Mar;52(3):871–6. doi: 10.1128/JCM.02876-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Brubaker L, Putonti C, Dong Q, Wolfe AJ. The human urobiome. Mamm Genome. 2021. Aug;32(4):232–8. doi: 10.1007/s00335-021-09862-8 [DOI] [PubMed] [Google Scholar]
  • 12.Carnes MU, Siddiqui NY, Karstens L, Gantz MG, Dinwiddie DL, Sung VW, et al. Urinary microbiome community types associated with urinary incontinence severity in women. Am J Obstet Gynecol. 2024. Mar;230(3):344.e1–344.e20. doi: 10.1016/j.ajog.2023.10.036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes Targets Ther. 2021. Aug;Volume 14:3567–602. doi: 10.2147/DMSO.S319895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Magliano D, Boyko EJ. IDF diabetes atlas. 10th edition. Brussels: International Diabetes Federation; 2021. [PubMed] [Google Scholar]
  • 15.Magliano DJ, Chen L, Islam RM, Carstensen B, Gregg EW, Pavkov ME, et al. Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings. Lancet Diabetes Endocrinol. 2021. Apr;9(4):203–11. doi: 10.1016/S2213-8587(20)30402-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Zhang K, Kan C, Han F, Zhang J, Ding C, Guo Z, et al. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019. JAMA Pediatr. 2023. Aug 1;177(8):837. doi: 10.1001/jamapediatrics.2023.2029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Nagl K, Waldhör T, Hofer SE, Blauensteiner N, Fritsch M, Fröhlich-Reiterer E, et al. Ongoing Increase in Incidence of Diabetes in Austrian Children and Adolescents (1989–2021): Results from a Nationwide Registry. Habeb AM, editor. Pediatr Diabetes. 2023. Aug 18;2023:1–7. [Google Scholar]
  • 18.Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022. Jan;183:109119. doi: 10.1016/j.diabres.2021.109119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mohanty S, Kamolvit W, Scheffschick A, Björklund A, Tovi J, Espinosa A, et al. Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder. Nat Commun. 2022. Sep 20;13(1):4983. doi: 10.1038/s41467-022-32636-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Natesan V, Kim SJ. Diabetic Nephropathy—a Review of Risk Factors, Progression, Mechanism, and Dietary Management. Biomol Ther. 2021. Jul 1;29(4):365–72. doi: 10.4062/biomolther.2020.204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. Mar 29;n71. doi: 10.1136/bmj.n71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Brubaker L, Gourdine JPF, Siddiqui NY, Holland A, Halverson T, Limeria R, et al. Forming Consensus To Advance Urobiome Research. mSystems. 2021;6(4). doi: 10.1128/mSystems.01371-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Boutron I, Page M, Higgins J, Altman D, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies [last updated August 2022]. In: Cochrane Handbook for Systematic Reviews of Interventions version 65 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA [Internet]. Cochrane; 2024. www.training.cochrane.org/handbook
  • 24.Furuya-Kanamori L, Xu C, Hasan SS, Doi SA. Quality versus Risk-of-Bias assessment in clinical research. J Clin Epidemiol. 2021. Jan;129:172–5. doi: 10.1016/j.jclinepi.2020.09.044 [DOI] [PubMed] [Google Scholar]
  • 25.National Heart, Lung and Blood Institute (NHLBI). Quality Assessment of Case-Control Studies [Internet]. National Institutes of Health United States Study of Quality Assessment Tools. 2021. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
  • 26.Liu F, Ling Z, Xiao Y, Lv L, Yang Q, Wang B, et al. Dysbiosis of urinary microbiota is positively correlated with Type 2 diabetes mellitus [Internet]. Vol. 8, Oncotarget. 2017. p. 3798–810. Available from: www.impactjournals.com/oncotarget/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ling Z, Liu F, Shao L, Cheng Y, Li L. Dysbiosis of the urinary microbiota associated with urine levels of proinflammatory chemokine interleukin-8 in female type 2 diabetic patients. Front Immunol. 2017. Aug 25;8(AUG). doi: 10.3389/fimmu.2017.01032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liu F, Ling Z, Xiao Y, Yang Q, Wang B, Zheng L, et al. Alterations of urinary microbiota in type 2 diabetes mellitus with hypertension and/or hyperlipidemia. Front Physiol. 2017. Mar 3;8(MAR). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Liu F, Ling Z, Tang C, Yi F, Chen YQ. Moderation effects of food intake on the relationship between urinary microbiota and urinary interleukin-8 in female type 2 diabetic patients. PeerJ. 2020;2020(1). doi: 10.7717/peerj.8481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Araujo R, Merino-Ribas A, Pereira L, Campos J, Silva N, Alencastre IS, et al. The urogenital microbiome in chronic kidney disease patients on peritoneal dialysis. Nefrología. 2023. Aug; [DOI] [PubMed] [Google Scholar]
  • 31.Yang Y, Ma C, Li S, Cai W, Dai W, Zhang X, et al. Urinary microbiota and serum metabolite analysis in patients with diabetic kidney disease. Heliyon. 2023. Aug 1;9(8). doi: 10.1016/j.heliyon.2023.e17040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rani A, Ranjan R, McGee HS, Andropolis KE, Panchal DV, Hajjiri Z, et al. Urinary microbiome of kidney transplant patients reveals dysbiosis with potential for antibiotic resistance. Transl Res. 2017. Mar 1;181:59–70. doi: 10.1016/j.trsl.2016.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kramer H, Kuffel G, Thomas-White K, Wolfe AJ, Vellanki K, Leehey DJ, et al. Diversity of the midstream urine microbiome in adults with chronic kidney disease. Int Urol Nephrol. 2018. Jun 1;50(6):1123–30. doi: 10.1007/s11255-018-1860-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Li X, Tang Y, Xu Z, Lin H, Wei S, Sheng J, et al. Impact of coexisting type 2 diabetes mellitus on the urinary microbiota of kidney stone patients. PeerJ. 2024. Feb 26;12:e16920. doi: 10.7717/peerj.16920 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chen J, Zhao J, Cao Y, Zhang G, Chen Y, Zhong J, et al. Relationship between alterations of urinary microbiota and cultured negative lower urinary tract symptoms in female type 2 diabetes patients. BMC Urol. 2019. Aug 22;19(1). doi: 10.1186/s12894-019-0506-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Penckofer S, Limeira R, Joyce C, Grzesiak M, Thomas-White K, Wolfe AJ. Characteristics of the microbiota in the urine of women with type 2 diabetes. J Diabetes Complications. 2020. Jun 1;34(6). doi: 10.1016/j.jdiacomp.2020.107561 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hrbacek J, Tlaskal V, Cermak P, Hanacek V, Zachoval R. Bladder Microbiota Are Associated with Clinical Conditions That Extend beyond the Urinary Tract. Microorganisms. 2022. May 1;10(5). doi: 10.3390/microorganisms10050874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Li Y, Gao F, Chen J, Fan X, Zhan W, Wu P, et al. Characteristics of urinary microflora in women with type 2 diabetic peripheral neuropathy without lower urinary tract symptoms; [无下尿路症状的女性2型糖尿病周围神经病变患者的尿液菌群特征]. Chin J Urol. 2020; [Google Scholar]
  • 39.Liu F, Ling Z, Xiao Y, Yang Q, Zheng L, Jiang P, et al. Characterization of the urinary microbiota of elderly women and the effects of type 2 diabetes and urinary tract infections on the microbiota [Internet]. Vol. 8, Oncotarget. 2017. p. 100678–90. Available from: www.impactjournals.com/oncotarget/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Düzgün Ç, Dede S, Karakuş E, Adaş M, Bilen Ö. Biochemical analysis of microbiotas obtained from healthy, prediabetic, type 2 diabetes, and obese individuals. Turk J Biochem. 2022; [Google Scholar]
  • 41.Lin HJ, Chuang HN, Jhan PP, Ye HY, Lee IT, Hsiao TH, et al. Pyuria Is Associated with Dysbiosis of the Urinary Microbiota in Type 2 Diabetes Patients Receiving Sodium–Glucose Cotransporter 2 Inhibitors. Microbiol Res. 2023. Mar 1;14(1):34–41. [Google Scholar]
  • 42.Calvigioni M, Biancalana E, Mazzantini D, Celandroni F, Rossi C, Mengozzi A, et al. In-depth Microbiological Characterization of Urine From Subjects With Type 2 Diabetes. J Clin Endocrinol Metab. 2024. Jun 13;dgae389. doi: 10.1210/clinem/dgae389 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kim K, Lee S, Park SC, Kim NE, Shin C, Lee SK, et al. Role of an unclassified Lachnospiraceae in the pathogenesis of type 2 diabetes: a longitudinal study of the urine microbiome and metabolites. Exp Mol Med. 2022. Aug 1;54(8):1125–32. doi: 10.1038/s12276-022-00816-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Patel NB, Obregón-Tito AJ, Tito RY, Trujillo-Villaroel O, Marin-Reyes L, Troncoso-Corzo L, et al. Citroniella saccharovorans gen. nov. sp. nov., a member of the family Peptoniphilaceae isolated from a human fecal sample from a coastal traditional community member. Int J Syst Evol Microbiol. 2019. Apr 1;69(4):1142–8. doi: 10.1099/ijsem.0.003287 [DOI] [PubMed] [Google Scholar]
  • 45.He M, Wei W, Zhang Y, Xiang Z, Peng D, Kasimumali A, et al. Gut microbial metabolites SCFAs and chronic kidney disease. J Transl Med. 2024. Feb 18;22(1):172. doi: 10.1186/s12967-024-04974-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Facchin S, Bertin L, Bonazzi E, Lorenzon G, De Barba C, Barberio B, et al. Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications. Life. 2024. Apr 26;14(5):559. doi: 10.3390/life14050559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024. Aug;24(8):577–95. doi: 10.1038/s41577-024-01014-8 [DOI] [PubMed] [Google Scholar]
  • 48.Nunn KL, Forney LJ. Unraveling the Dynamics of the Human Vaginal Microbiome. Yale J Biol Med. 2016. Sep;89(3):331–7. [PMC free article] [PubMed] [Google Scholar]
  • 49.Hugenholtz F, Van Der Veer C, Terpstra ML, Borgdorff H, Van Houdt R, Bruisten S, et al. Urine and vaginal microbiota compositions of postmenopausal and premenopausal women differ regardless of recurrent urinary tract infection and renal transplant status. Sci Rep. 2022. Feb 17;12(1):2698. doi: 10.1038/s41598-022-06646-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Vaughan MH, Mao J, Karstens LA, Ma L, Amundsen CL, Schmader KE, et al. The Urinary Microbiome in Postmenopausal Women with Recurrent Urinary Tract Infections. J Urol. 2021. Nov;206(5):1222–31. doi: 10.1097/JU.0000000000001940 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Zheng N, Guo R, Wang J, Zhou W, Ling Z. Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review. Front Cell Infect Microbiol. 2021. Nov 22;11:792787. doi: 10.3389/fcimb.2021.792787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Maillet F, Passeron A, Podglajen I, Ranque B, Pouchot J. Lactobacillus delbrueckii urinary tract infection in a male patient. Médecine Mal Infect. 2019. May;49(3):226–8. doi: 10.1016/j.medmal.2018.11.006 [DOI] [PubMed] [Google Scholar]
  • 53.Hori E, Nakamura M, Tamura H. A diagnostically challenging case of pyelonephritis caused by Lactobacillus. Clin Case Rep. 2022. Jun;10(6):e5999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, et al. The female urinary microbiome in urgency urinary incontinence. Am J Obstet Gynecol. 2015. Sep;213(3):347.e1–347.e11. doi: 10.1016/j.ajog.2015.07.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Kuo IC, Lee JJ, Hwang DY, Lim LM, Lin HYH, Hwang SJ, et al. Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3–5. Sci Rep. 2020. Nov 10;10(1):19460. doi: 10.1038/s41598-020-76520-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Zaidi SMJ, Kaneez M, Almas T, Fatima L, Safian HA, Jamal AM, et al. Gauging the Risk Factors for Asymptomatic Bacteriuria in Type-2 Diabetic Women: A Case-Control Study. Cureus [Internet]. 2020. Jul 8 [cited 2024 Mar 5]; Available from: https://www.cureus.com/articles/35887-gauging-the-risk-factors-for-asymptomatic-bacteriuria-in-type-2-diabetic-women-a-case-control-study [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Yoo J, Groer M, Dutra S, Sarkar A, McSkimming D. Gut Microbiota and Immune System Interactions. Microorganisms. 2020. Oct 15;8(10):1587. doi: 10.3390/microorganisms8101587 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Zongxin Ling

19 Nov 2024

PONE-D-24-45699The urinary microbiome in association with diabetes and diabetic kidney disease: A systematic reviewPLOS ONE

Dear Dr. Graells,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 03 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Zongxin Ling

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found athttps://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf andhttps://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following financial disclosure: [We acknowledge funding from the Swedish research council (Vetenskapsrådet grant number 2019-01015, 2019-01471 and 2020-0243), from the Swedish heart lung foundation (Hjärt-Lungfonden grant number 2021-0357 and 2023-0687), and from Center of clinical research (CKF) in Region Dalarna, Falun, Sweden. Dr Ahmad was supported by research grants from FORMAS –Early Career Grant (no. 2020-00989), Swedish Research Council-Early Career Grant (no. 2022-01460), EFSD/Novo Nordisk and EpiHealth]. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. We note that there is identifying data in the Supporting Information file <Supp_information_SysRev_DM_Urobiome.docx>. Due to the inclusion of these potentially identifying data, we have removed this file from your file inventory. Prior to sharing human research participant data, authors should consult with an ethics committee to ensure data are shared in accordance with participant consent and all applicable local laws. Data sharing should never compromise participant privacy. It is therefore not appropriate to publicly share personally identifiable data on human research participants. The following are examples of data that should not be shared: -Name, initials, physical address-Ages more specific than whole numbers-Internet protocol (IP) address-Specific dates (birth dates, death dates, examination dates, etc.)-Contact information such as phone number or email address-Location data-ID numbers that seem specific (long numbers, include initials, titled “Hospital ID”) rather than random (small numbers in numerical order) Data that are not directly identifying may also be inappropriate to share, as in combination they can become identifying. For example, data collected from a small group of participants, vulnerable populations, or private groups should not be shared if they involve indirect identifiers (such as sex, ethnicity, location, etc.) that may risk the identification of study participants. Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long. Please remove or anonymize all personal information (name, initials), ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. Please note that spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 5. As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following:  A numbered table of all studies identified in the literature search, including those that were excluded from the analyses.   For every excluded study, the table should list the reason(s) for exclusion.   If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed.  A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study:  Name of data extractors and date of data extraction  Confirmation that the study was eligible to be included in the review.   All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses.  If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group.  If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome.  Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome.   An explanation of how missing data were handled.  This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected.  

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors reviewed urinary microbiome in patients with diabetic kidney disease. This review is valuable. However, there are still some issues.

1. Line 91. As a systematic review, SCOPUS and PUBMED databases are not enough. Databases such as PubMed/Medline, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials should be included.

2. The abundance of urine microbiome is relatively low, so different detection methods may bring large errors. There is a big gap between the technology of 20 years ago and the technology of today, which may produce a large bias in the analysis. It is suggested that the authors change the search range to nearly 10 years. For example, from 2014 to 2024.

3. There is only one figure and one table in the manuscript. Why did the authors include so much data in the supplementary material? Some data should be moved from the supplementary material.

Reviewer #2: This is a well-structured and informative review of the current knowledge on the urobiome and its association with diabetes mellitus and diabetic kidney disease. The review effectively highlights the emerging field of urobiome research and its potential implications for understanding and managing kidney disease.

Here are some areas for potential improvement:

While the review provides a good overview of the trends in the literature, a deeper analysis of the specific microbial taxa and functional pathways associated with diabetes and kidney disease could be beneficial.

The review could discuss in more detail the methodological limitations of the included studies, such as potential biases in sample collection and processing, and the impact of these limitations on the overall findings.

The review could conclude with a discussion of future research directions, including the need for larger, well-designed studies to confirm the findings and explore the mechanisms underlying the associations between the urobiome and diabetes.

While you summarize results on richness, alpha/beta diversity, and specific bacterial taxa, consider offering a more interpretive analysis. Explore potential connections between specific microbial changes and diabetes or DKD.

Discuss the limitations of the included studies, such as small sample sizes, cross-sectional design, and heterogeneity in sample collection methods. Consider how these limitations might affect the generalizability of the findings.

Conclude by outlining potential future research directions. You could expand on specific areas of future research. This could include

• investigating the influence of specific dietary patterns on the urobiome in diabetes.

• exploring the potential for manipulating the urobiome through probiotics or other interventions.

• investigating the role of the urobiome in the early stages of diabetes development.

You could briefly mention the potential implications of these findings for understanding and managing diabetes and DKD.

Briefly discuss potential mechanisms by which the observed changes in the urobiome might influence diabetes and DKD. For example, how could the decrease in butyrate-producing bacteria contribute to disease?

Please provide a full search strategy for all databases.

Reviewer #3: Graells et al. have performed a systematic review on the association of urinary microbiome with diabetes and diabetic kidney diseases. The study findings are interesting and the manuscript is well-written. These are my comments:

- Abstract should have a structure of background, methods, results, and conclusion.

- The introduction section is rather long in its current format. The authors should focus on the main ideas related to the topic and try to emphasize the gaps in knowledge.

- The results section could be organized by adding subheadings.

- A supplementary table containing the search strategy and the exact words searched in each database could be helpful for the reproducibility of the study.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2025 Jan 31;20(1):e0317960. doi: 10.1371/journal.pone.0317960.r002

Author response to Decision Letter 0


19 Dec 2024

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors reviewed urinary microbiome in patients with diabetic kidney disease. This review is valuable. However, there are still some issues.

1. Line 91. As a systematic review, SCOPUS and PUBMED databases are not enough. Databases such as PubMed/Medline, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials should be included.

Authors’ response: Thank you for pointing out that fact. We have updated the Methods Search Strategy section to include these new database searches and to update the previous searches. We have now included until the end of November a search in MEDLINE Ovid, Web of Science and EMBASE where we found 38,86 and 87 records, respectively. Duplicates were 37, 45 and 63 in MEDLINE Ovid, Web of Science and EMBASE, respectively. One, 17 and 21 were articles types in MEDLINE Ovid, Web of Science and EMBASE, respectively, not included in our analyses such as reviews, conference abstracts. Twenty-one and three articles were excluded after screening title and abstract in Web of Science and EMBASE, respectively. Hence, in the end only three articles were eligible for full screening from Web of Science. In the end, none of them were included in the analysis after full screening as they did not fulfil the inclusion criteria.

We have also searched the Cochrane Central Register of Controlled Trials where there were no matching for Reviews, Protocols, Trials, Editorials, Special collections or Clinical answers following a TITLE-ABS-KEY search [[ 0 Cochrane Reviews matching "urobiome" OR "urinary microbiome" OR "urinary microbiota" OR "urinary tract microb*" OR "urine microb*" OR "urogenital microbiome" OR "urogenital microbiota" in Title Abstract Keyword AND "kidney disease*" OR "chronic kidney disease" OR "diabetes" OR "albuminuria" OR "diabetic nephropathy" OR "end stage renal disease*" OR "renal disease*" in Title Abstract Keyword - (Word variations have been searched) ]]. All this is specified in the Methods search strategy.

2. The abundance of urine microbiome is relatively low, so different detection methods may bring large errors. There is a big gap between the technology of 20 years ago and the technology of today, which may produce a large bias in the analysis. It is suggested that the authors change the search range to nearly 10 years. For example, from 2014 to 2024.

Authors’ response: Thank you for this pointing this fact. It is completely true that technology has changed a lot in 20 years. And, we could have searched only one decade, but we did not want to miss anything that could have been published. However, the first article that fulfilled the inclusion criteria was published only 7 years ago, in 2017. Hence, although technology has changed in 20 years, we believe that this is not affecting our analysis as articles selected following the inclusion criteria are from 2017 onwards.

3. There is only one figure and one table in the manuscript. Why did the authors include so much data in the supplementary material? Some data should be moved from the supplementary material.

Authors’ response: Thank you for noticing that we have conducted a thorough analysis of each of the articles. We have presented all data we have checked for each of the articles in the supplementary information. We believe that the summarized and key information is the one presented in Table 1. That is why, Table 1 is so extensive, and we decided still to make available all the data collected in the supplementary information for interested researchers. We believe that the article is easier and more attractive to read by summarizing the most important information in a single table in the main manuscript. However, we are willing to reorganize if the Editor agrees that this would be an improvement of the manuscript.

Reviewer #2: This is a well-structured and informative review of the current knowledge on the urobiome and its association with diabetes mellitus and diabetic kidney disease. The review effectively highlights the emerging field of urobiome research and its potential implications for understanding and managing kidney disease.

Here are some areas for potential improvement:

While the review provides a good overview of the trends in the literature, a deeper analysis of the specific microbial taxa and functional pathways associated with diabetes and kidney disease could be beneficial.

Authors’ response: Thank you for this comment. We have expanded the discussion and references with the following. “Generally, adults with diabetes and/or chronic kidney disease show lower abundance of short-chain fatty acids producing bacteria in the gut compared to healthy controls [4,45]. This systematic review reveals that diabetic individuals have similar trends but also differences in their urinary and urogenital microbiota with lower relative abundance of short-fatty acid butyrate-producing bacteria of the family Peptoniphilaceae. Butyrate is the main source of colonocyte metabolism, it is an enhancer of the integrity of the epithelium, and it decreases inflammation in the mucosa while promoting electrolyte absorption in the gut [46]. Moreover, dissociated butyric acid has an antibacterial effect [46] and butyryl-CoA regulates transcription and modifies proteins [46,47]. We hypothesize that butyrate could also promote epithelium integrity and reduce inflammation in the urinary tract. Hence, depletion of butyrate-producing bacteria such as Peptoniphilus, Anaerococcus, and Gallicola in diabetic individuals could induce inflammation and contribute to the high onset of urinary infections in diabetic individuals in the urinary tract and induce inflammation in the renal blood vessels which could worsen kidney disease. This theory will need further studies to be confirmed but it could help to understand if the use of butyrate as a postbiotic could improve urinary functionality in association with diabetes and kidney disease.”

The review could discuss in more detail the methodological limitations of the included studies, such as potential biases in sample collection and processing, and the impact of these limitations on the overall findings.

Authors’ response: Thank you for this comment. We have expanded the limitations section with lines 335-343.

The review could conclude with a discussion of future research directions, including the need for larger, well-designed studies to confirm the findings and explore the mechanisms underlying the associations between the urobiome and diabetes.

Authors’ response: Thank you for this comment. We have expanded the future perspectives section with lines 358-367.

While you summarize results on richness, alpha/beta diversity, and specific bacterial taxa, consider offering a more interpretive analysis. Explore potential connections between specific microbial changes and diabetes or DKD.

Authors’ response: Thank you for this comment. We have expanded the discussion and references with the following. “Generally, adults with diabetes and/or chronic kidney disease show lower abundance of short-chain fatty acids producing bacteria in the gut compared to healthy controls [4,45]. This systematic review reveals that diabetic individuals have similar trends but also differences in their urinary and urogenital microbiota with lower relative abundance of short-fatty acid butyrate-producing bacteria of the family Peptoniphilaceae. Butyrate is the main source of colonocyte metabolism, it is an enhancer of the integrity of the epithelium, and it decreases inflammation in the mucosa while promoting electrolyte absorption in the gut [46]. Moreover, dissociated butyric acid has an antibacterial effect [46] and butyryl-CoA regulates transcription and modifies proteins [46,47]. We hypothesize that butyrate could also promote epithelium integrity and reduce inflammation in the urinary tract. Hence, depletion of butyrate-producing bacteria such as Peptoniphilus, Anaerococcus, and Gallicola in diabetic individuals could induce inflammation and contribute to the high onset of urinary infections in diabetic individuals in the urinary tract and induce inflammation in the renal blood vessels which could worsen kidney disease. This theory will need further studies to be confirmed but it could help to understand if the use of butyrate as a postbiotic could improve urinary functionality in association with diabetes and kidney disease.”

Discuss the limitations of the included studies, such as small sample sizes, cross-sectional design, and heterogeneity in sample collection methods. Consider how these limitations might affect the generalizability of the findings.

Authors’ response: Thank you for this comment. We have expanded the limitations section with lines 335-343.

Conclude by outlining potential future research directions. You could expand on specific areas of future research. This could include

• investigating the influence of specific dietary patterns on the urobiome in diabetes.

• exploring the potential for manipulating the urobiome through probiotics or other interventions.

• investigating the role of the urobiome in the early stages of diabetes development.

Authors’ response: Thank you for this comment. We have expanded the future perspectives section with lines 358-367.

You could briefly mention the potential implications of these findings for understanding and managing diabetes and DKD.

Briefly discuss potential mechanisms by which the observed changes in the urobiome might influence diabetes and DKD. For example, how could the decrease in butyrate-producing bacteria contribute to disease?

Authors’ response: Thank you for this comment. We have expanded the discussion and references with the following. “Generally, adults with diabetes and/or chronic kidney disease show lower abundance of short-chain fatty acids producing bacteria in the gut compared to healthy controls [4,45]. This systematic review reveals that diabetic individuals have similar trends but also differences in their urinary and urogenital microbiota with lower relative abundance of short-fatty acid butyrate-producing bacteria of the family Peptoniphilaceae. Butyrate is the main source of colonocyte metabolism, it is an enhancer of the integrity of the epithelium, and it decreases inflammation in the mucosa while promoting electrolyte absorption in the gut [46]. Moreover, dissociated butyric acid has an antibacterial effect [46] and butyryl-CoA regulates transcription and modifies proteins [46,47]. We hypothesize that butyrate could also promote epithelium integrity and reduce inflammation in the urinary tract. Hence, depletion of butyrate-producing bacteria such as Peptoniphilus, Anaerococcus, and Gallicola in diabetic individuals could induce inflammation and contribute to the high onset of urinary infections in diabetic individuals in the urinary tract and induce inflammation in the renal blood vessels which could worsen kidney disease. This theory will need further studies to be confirmed but it could help to understand if the use of butyrate as a postbiotic could improve urinary functionality in association with diabetes and kidney disease.”

Authors’ response: Thank you for this comment.

Please provide a full search strategy for all databases.

Authors’ response: Thank you for this comment. We have updated the Methods Search Strategy section to include new databases in this analysis. We have updated the information provided and we have made available our search strategy in the following lines: “A comprehensive literature search on different databases was conducted from 1st January 2000 until 28th November 2024. The search included the following terms [("urobiome" OR "urinary microbiome" OR "urinary microbiota" OR "urinary tract microb*" OR "urine microb*" OR "urogenital microbiome" OR "urogenital microbiota") AND ("kidney disease*" OR "chronic kidney disease" OR "diabetes" OR "albuminuria" OR "diabetic nephropathy" OR "end stage renal disease*" OR "renal disease*")]. We used the ‘TITLE-ABS-KEY’ search in SCOPUS and Cochrane Central Register of Controlled Trials databases, the ‘Keyword’ in advanced search in MEDLINE-Ovid and EMBASE databases, while ‘ALL FIELDS’ were used in Web of Science and PUBMED databases.”.

Reviewer #3: Graells et al. have performed a systematic review on the association of urinary microbiome with diabetes and diabetic kidney diseases. The study findings are interesting and the manuscript is well-written. These are my comments:

- Abstract should have a structure of background, methods, results, and conclusion.

Authors’ response: Thank you for this comment. Now, we have added these sections in the abstract.

- The introduction section is rather long in its current format. The authors should focus on the main ideas related to the topic and try to emphasize the gaps in knowledge.

Authors’ response: In the revised version of the manuscript, we have shortened the introduction part.

- The results section could be organized by adding subheadings.

Authors’ response: Thank you for this comment. Now, we have added these sections (3.1 Selected studies; 3.2 Diversity and richness indexes; and 3.3 Differences in microbial microbial taxa).

- A supplementary table containing the search strategy and the exact words searched in each database could be helpful for the reproducibility of the study.

Authors’ response: Thank you for this comment. We have updated the Methods Search Strategy section to include new databases in this analysis. We have updated the information provided including a supplementary table with the details of the search startegy and we have made available our search strategy in the following lines: “A comprehensive literature search on different databases was conducted from 1st January 2000 until 28th November 2024. The search included the following terms [("urobiome" OR "urinary microbiome" OR "urinary microbiota" OR "urinary tract microb*" OR "urine microb*" OR "urogenital microbiome" OR "urogenital microbiota") AND ("kidney disease*" OR "chronic kidney disease" OR "diabetes" OR "albuminuria" OR "diabetic nephropathy" OR "end stage renal disease*" OR "renal disease*")]. We used the ‘TITLE-A

Decision Letter 1

Zongxin Ling

8 Jan 2025

The urinary microbiome in association with diabetes and diabetic kidney disease: A systematic review

PONE-D-24-45699R1

Dear Dr. Graells,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Zongxin Ling

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you very much. You guys solved all my problems. I think the present article is worth publishing.

Reviewer #2: the aim of this systematic review is to gather available data and synthetise the main

80 findings about the urobiome, particularly, the urinary microbiota in association with diabetes and

81 kidney conditions derived from diabetes such as CKD or ESRD. All of my comments have been responded satisfactorily.

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Zongxin Ling

22 Jan 2025

PONE-D-24-45699R1

PLOS ONE

Dear Dr. Graells,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Zongxin Ling

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    pone.0317960.s001.docx (185.6KB, docx)
    S1 Checklist. PRISMA 2020 checklist.

    (DOCX)

    pone.0317960.s002.docx (31.7KB, docx)
    S1 Table. Original records retrieved from Pubmed, SCOPUS, MEDLINE-Ovid, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials databases.

    (XLSX)

    pone.0317960.s003.xlsx (71.6KB, xlsx)

    Data Availability Statement

    Data presented and gathered in this systematic review are fully shown in this manuscript or in the supplementary information.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES